Global HIV/AIDS Diagnostics Market Size, Segmentation, Trends and Growth Analysis Forecast by 2030

HIV/AIDS Diagnostics Market Overview and Analysis:

The HIV/AIDS Diagnostics Market is currently valued at USD 3.98 billion in the year 2022 and is expected to register a CAGR of 12.78% over the forecast period, 2023-2030.

Get Complete Analysis Of The Report - Download Free Sample PDF

The report HIV/AIDS diagnostics is used to investigate the existence of the human immune-deficiency virus, in saliva, serum, or urine. HIV/AIDS diagnostics helps to detect antibodies, RNA, or antigens. Blood tests are the most regular way to make a diagnosis of HIV. HIV is most commonly diagnosed by doing a urine test and blood test. 

Factors such as the increasing prevalence of HIV along with new initiatives and product launches are the primary reasons for the growth of the market. 

HIV/AIDS Diagnostics Market Latest Trends:

The global HIV diagnostics market is booming due to rising demand for rapid testing and point-of-care (PoC) HIV tests around the world. In addition, people's disposable income is increasing, which is encouraging the HIV diagnostics market growth. Furthermore, an important advance in HIV diagnostics has been the decoupling of HIV screening immunoassays from the clinical laboratory with the development of rapid HIV tests.

Segmentation:

The HIV/AIDS Diagnostics Market is Segment

By Product

• Consumables
• Instruments
• Software and services

By Test Type

• Antibody Tests
• Viral Load Tests
• CD4 Tests
• Others

End User

• Diagnostic Laboratories
• Hospitals
• Others

Geography

• North America
• Europe
• Asia-Pacific
• Middle East
• Africa
• South America

The report offers the value (in USD million) for the above segments.

For Detailed Market Segmentation - Download Free Sample PDF

Drivers:

Growing Prevalence of HIV/AIDS

As per the latest update published by WHO reported that in July 2023, there were an estimated 39.0 million [33.1–45.7 million] people living with HIV at the end of 2022, two-thirds of whom (25.6 million) are in the WHO African Region. In 2022, 630,000 [480,000–880,000] people died from HIV-related causes, and 1.3 million [1.0–1.7 million] people acquired HIV. Furthermore, HIV.Gov in July 2023, reported that 38 million people worldwide are currently living with HIV or AIDS. The Global HIV and AIDS Epidemic. Thus, instances show the high number of HIV cases is creating a growing demand for HIV diagnostics, thereby fueling the growth of the studied market.

Increasing Government Initiatives

In July 2023, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) is the U.S. Government’s response to the global HIV/AIDS epidemic and represents the largest commitment by any nation to address a single disease in history. Through PEPFAR, which was launched in 2003, the U.S. has supported a world safer and more secure from infectious disease threats. It has demonstrably strengthened the global capacity to prevent, detect, and respond to new and existing risks—which ultimately enhances global health security and protects America’s borders. Thus, such instances are fueling the growth of the studied market.

Restraints:

Lack of Mandates for Nucleic Acid Tests in Developing Countries

However, the lack of mandates for nucleic acid tests in developing countries is likely to hinder market growth.

COVID-19 Impact On HIV/AIDS Diagnostics Market

COVID-19 caused a dramatic decline in HIV testing and, as a consequence, a much lower number of new HIV diagnoses. In May 2022, an article published titled "COVID Caused Drop-in HIV Testing, Diagnoses" stated that the Centers for Disease Control and Prevention (CDC) 2020 HIV surveillance report showed COVID disruptions. The COVID-19 pandemic in the United States led to disruptions in HIV testing services and access to clinical services throughout 2020. Similarly, in December 2021, a report published by the Government of Canada, titled "HIV in Canada: 2020 Surveillance Highlights" stated that the COVID-19 pandemic resulted in a decreased demand for, and ability to provide, services related to sexually transmitted and bloodborne infections, including HIV testing. This may have had an impact on observed new diagnosis rates for HIV in 2020. Hence, the COVID-19 pandemic has a negative impact on market growth. However, in the future, the market is likely to grow.

Segmentation Analysis:

Antibody Test Segment Accounts for the Large Market Share Over the Forecast Period

The Antibody test detects HIV antibodies in blood or saliva. The immune system makes antibodies when bacteria or viruses enter the body. An HIV antibody test can determine if the person is positive after 3–12 weeks after infection. That's because it can take a few weeks or longer for the immune system to make antibodies to HIV. The patient can do an HIV antibody test in privacy at home with the kits.

Diagnostic Laboratories is Expected to Witness Significant growth Over the Forecast Period

Most HIV infections can lead to serious health problems and these tests are done in USFDA-approved laboratories. The access and accuracy of diagnostics labs for HIV testing are driving the growth of the studied segment over the forecast period.

North America Dominates the Market and Expected to Witness Significant Over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, the high prevalence of HIV/AIDS in the region, and established healthcare infrastructure are some of the key factors accountable for its large share. Additionally, in December 2021, the Centers for Disease Control and Prevention (CDC) awarded USD 22 million to nearly 30 organizations around the world to combat antimicrobial resistance (AR) infectious diseases (including HIV), and other healthcare threats through the establishment of two new networks namely the Global Action in Healthcare Network (GAIHN) and the Global AR Laboratory and Response Network (Global AR Lab & Response Network). Thus, increasing investments and the establishment of a global network for supporting diagnostics will drive the market.

Get Complete Analysis Of The Report - Download Free Sample PDF

Competitive Landscape:

The HIV/AIDS diagnostics market is moderately competitive and consists of several major players. Some of the market players are

• Siemens Healthineers
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Danaher Corporation
• Thermo-Fisher Scientific Inc.
• Merck KGaA
• Becton
• Dickinson & Company
• Hologic Inc.
• Bio-Rad Laboratories
• among others.

Recent Developments

1) In May 2022, THE Amref Health Africa-Tanzania launched the “Afya Kamilifu’ project in the Mara Region to prevent HIV. The project is sponsored by the Centre for Disease Control and Prevention (CDC). Under this HIV self-test kits were made available at all health centers in the region.

2) In May 2022, Roche through its Global Access Program, partnered with The Global Fund to improve the diagnosis of HIV by building local capacity to tackle fundamental infrastructure challenges for generating and delivering diagnostic results and managing healthcare waste. This includes building effective processes to collect, transport, test samples, and return the results to patients for timely clinical interventions, as well as addressing challenges arising from a lack of network infrastructure, workforce capacity, access to roads, and IT systems.

Frequently Asked Questions (FAQ) :

Q1. What is the current HIV/AIDS Diagnostics Market size?

Q2. What is the Growth Rate of the HIV/AIDS Diagnostics Market?

Q3. What Impact did COVID-19 have on the HIV/AIDS Diagnostics Market?

Q4. Which Region is expected to hold the highest Market share?